The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

The trial enrolled patients with moderately to severely active Crohn's disease who had experienced ... locally advanced or metastatic breast cancer who have BRCA1 or BRCA2 mutations and have ...

For patients diagnosed with “Crohn’s disease” (CD) or “indeterminate colitis ... There were four deaths in the PSC-IBD group from IBD related causes (all from metastatic carcinoma) and five deaths ...

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume ...

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods.

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume ...